HIV Resistance and Treatment Strategies
Completed
Conditions studied: HIV Infections
In brief
The purpose of this observational study is to characterize which immune system cells hide the latent reservoir of HIV by counting the number of latent HIV in different subsets of CD4 cells. Observations will also be made on other possible mechanisms of HIV persistence by looking at cellular factors such as APOBEC3 and drug transporters. The purpose of this study is to develop new strategies to reduce and possibly eliminate the latent reservoir in HIV infected adults.
Key facts
- Study ID
- NCT00581802
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 89
- Starts
- 2007-01-01
- Expected to finish
- 2011-01-01
- Last updated by the study team
- 2012-05-04
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Viral load "blip" greater than 2,000 copies/ml during current suppressive regimen
- Consistent low level viral load (between 50 and 2,000 copies/ml) during current regimen
- Change in currently suppressing HAART before study entry
- Self-reported or clinician-reported nonadherence to earlier antiretroviral regimens
- Current substance abuse that, in the opinion of the investigator, will increase the risk of nonadherence
- Weight less than 110 lbs
- Blood transfusion within the 6 months prior to study entry
- Platelets less than 50 cells/mm3
- INR greater than 2.0 if participants are on warfarin
- Heart disease with recent angina or MI within 1 year prior to study entry
- Hematocrit 28% or less OR hemoglobin 8.0 g/dl or less
- Prior ART that included only one or two drugs
- Pregnancy
- Inclusion Criteria for Group 5:
- HIV infected
- Currently taking or about to begin raltegravir with optimized background HAART
- Exclusion Criteria:
- Current substance abuse that, in the opinion of the investigator, will increase the risk of nonadherence
- Weight less than 110 lbs
- Blood transfusion 6 months prior to study entry
- Platelets less than 50/mm3
- INR greater than 2.0 if participants are on warfarin
- Heart disease with recent angina or MI within 1 year prior to study entry
- • Hematocrit 28% or less OR hemoglobin 8.0 g/dl or less
- Pregnancy
Where it is running
- Comprehensive Care Clinic/Center for AIDS Research — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.